-The Economic Times Extension of life is priceless. Simply priceless." These were the words of Venkat Krishnan (name changed) to Novartis after receiving treatment with Glivec for about two years. Following his diagnosis with chronic myeloid leukaemia (CML), Venkat married his college sweetheart against the wishes of her family. After all, the prognosis in those days for people suffering from CML was not promising. Taking interferon, a powerful immune therapy, was the...
More »SEARCH RESULT
Total Matching Records found : 2827
Tribal affairs ministry against MoEF move to dilute forest rights Act- Liz Mathew and Neha Sethi
-Live Mint MoEF notification on 5 February says linear projects such as roads, canals wouldn't require gram sabha consent A move by the ministry of environment and forests (MoEF) to exempt promoters of so-called linear projects such as roads, pipelines and canals from seeking the consent of village councils in forest areas will likely be a non-starter unless the government moves to amend the forest rights Act (FRA). MoEF issued a notification on...
More »Patent war over drugs goes chronic -Rupali Mukherjee
-The Times of India MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market. Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster...
More »SC verdict on Novartis AG plea today
-Reuters Global drugmakers, battered by recent intellectual property decisions in the country, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country. Supreme Court is due to decide on April 1 whether or not Swiss giant Novartis AG's cancer treatment Glivec deserves a patent in the country. "Big Pharma is nervous because nothing has gone in their favour in the...
More »Aakash is no silver bullet-Akshat Rathi
-The Hindu The government needs to open its eyes and realise that the technological utopia it envisions in the low-cost tablet is no cure for poor education, poverty or inequality The last few days have brought the Aakash tablet back into the media limelight. Last Friday, Human Resource Development (HRD) Minister M.M. Pallam Raju said that troubles with the manufacturer could doom the project. But the next day, former HRD Minister Kapil...
More »
